Meta Pixel

News and Announcements

Actinogen Medical Raises $5.2m for Alzheimer’s Treatment

  • Published December 07, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

KEY TAKEAWAYS:

  • Actinogen Medical has raised $5.3 million to complete the second of three trials of Xanamem required by the US FDA.
  • Alzheimer’s disease is the second biggest killer of Australians.
  • There is a strong association between chronically raised cortisol levels in the blood and in the brain and the development of Alzheimer’s disease.

Alzheimer’s disease is the second biggest killer of Australians, but investors have just bet $5.3 million that a local listed company has the cure.

Actinogen backdoor-listed on the Australian Stock Exchange in 2014 in order to buy the global licence for Xanamem, a drug said to block the excess production of the hormone cortisol in the brain, from Edinburgh University.

The $5.28 million, raised via a placement at 4¢ a share that closed oversubscribed last week, follows an $11 million raising in 2015 and will allow Actinogen to complete the second of three trials of Xanamem required by the US Food & Drug Administration (FDA).

Xanamem was developed in response to evidence that there is a strong association between chronically raised cortisol levels in the blood and in the brain, and the development of Alzheimer’s disease said Actinogen managing director Dr Bill Ketelbey.

Cortisol is produced at times of physical and mental stress, and if it remains elevated for long periods of time, it can become toxic to the nerve cells in the brain. Several studies have shown an association between increased cortisol and cognitive decline.

About Actinogen Medical (ASX: ACW)

Actinogen Medical Limited (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.

Request Information

Capital Insights
Industrial AI does not fail on models. It fails on context.

Operational Intelligence connects fragmented operational data and systems across an industrial facility, including control systems, historians and equipment data, to give operators and AI tools a connected view of what a plant is actually doing. It sits within the broader industrial software and Asset Performance Management market, where predictive maintenance is one application among several, and can be deployed on premises, at the edge or in airgapped environments where operational data cannot leave the site.

Capital Insights
It looks like a fund with no thesis. It is not really a fund.

An umbrella fund structure holds multiple single-purpose sub-funds, each with its own unit class and segregated assets held in the trustee’s name. Investors select an individual project rather than acquiring exposure to the whole portfolio, which means they carry concentrated exposure to that project and do not obtain diversification across the fund’s other investments.

Join over 45,000+ sophisticated investors

Join Now